[AGIO] Agios Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 43.15 Change: 1.78 (4.3%)
Ext. hours: Change: 0 (0%)

chart AGIO

Refresh chart

Strongest Trends Summary For AGIO

AGIO is in the long-term down -63% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS-6 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 306.63% Sales Growth - Q/Q133.68% P/E-8.63
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-9.74% ROE-10.83% ROI
Current Ratio10.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin-51.61% Net Profit Margin-50.7% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.82 M Cash From Investing Activities44.99 M Cash From Operating Activities-25.59 M Gross Profit
Net Profit-4.96 M Operating Profit-5.2 M Total Assets474.34 M Total Current Assets364.14 M
Total Current Liabilities36.38 M Total Debt Total Liabilities47.52 M Total Revenue34.2 M
Technical Data
High 52 week75.11 Low 52 week42.73 Last close62.35 Last change5.93%
RSI68.62 Average true range2.74 Beta1.94 Volume828.59 K
Simple moving average 20 days13.04% Simple moving average 50 days18.89% Simple moving average 200 days3.15%
Performance Data
Performance Week5.16% Performance Month20.07% Performance Quart-5.23% Performance Half4.56%
Performance Year26.83% Performance Year-to-date35.22% Volatility daily2.87% Volatility weekly6.41%
Volatility monthly13.13% Volatility yearly45.49% Relative Volume130.51% Average Volume563.62 K
New High New Low

News

2020-05-30 11:31:03 | Why Is Agios Pharmaceuticals AGIO Up 25.8% Since Last Earnings Report?

2020-05-29 08:00:10 | Agios Presents Updated Data from the Phase 1 Dose-escalation Study of Vorasidenib in Patients with IDH-mutant Non-enhancing Glioma

2020-05-28 11:56:03 | Moving Average Crossover Alert: Agios Pharmaceuticals

2020-05-21 11:30:03 | Is Agios Pharmaceuticals AGIO Stock Outpacing Its Medical Peers This Year?

2020-05-19 07:00:10 | Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

2020-05-14 09:41:56 | Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

2020-05-13 17:01:10 | Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

2020-05-13 10:49:02 | Will Agios Pharmaceuticals Continue to Surge Higher?

2020-05-12 18:00:00 | Stocks To Watch: Agios Pharmaceuticals Sees RS Rating Jump To 85

2020-05-12 07:00:10 | Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

2020-05-07 10:18:02 | Why Agios AGIO Stock Might be a Great Pick

2020-05-03 08:14:18 | Analysts Are Upgrading Agios Pharmaceuticals, Inc. NASDAQ:AGIO After Its Latest Results

2020-05-01 08:10:42 | Brokers Are Upgrading Their Views On Agios Pharmaceuticals, Inc. NASDAQ:AGIO With These New Forecasts

2020-05-01 01:30:48 | Agios Pharmaceuticals Inc AGIO Q1 2020 Earnings Call Transcript

2020-04-30 18:15:29 | Edited Transcript of AGIO earnings conference call or presentation 30-Apr-20 12:00pm GMT

2020-04-30 09:05:01 | Agios Pharmaceuticals AGIO Reports Q1 Loss, Tops Revenue Estimates

2020-04-30 07:00:10 | Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response

2020-04-23 12:32:04 | Analysts Estimate Agios Pharmaceuticals AGIO to Report a Decline in Earnings: What to Look Out for

2020-04-16 07:00:10 | Agios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020

2020-04-16 06:03:22 | Here's Why We're Not Too Worried About Agios Pharmaceuticals's NASDAQ:AGIO Cash Burn Situation

2020-04-15 09:01:14 | Time to Pull the Trigger? RBC Offers 2 Stocks to Buy

2020-04-14 16:57:00 | Agios Pharmaceuticals Shows Improved Relative Strength; Still Shy Of Benchmark

2020-03-30 16:01:10 | Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase Deficiency

2020-03-27 15:50:15 | Hedge Funds Were Buying Agios Pharmaceuticals Inc AGIO Before The Coronavirus

2020-03-25 16:01:10 | Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb

2020-03-24 13:08:05 | Agios' IND for PKR Activator AG-946 Gets FDA Clearance

2020-03-23 07:00:10 | Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator

2020-03-14 11:30:03 | Why Is Agios Pharmaceuticals AGIO Down 28.7% Since Last Earnings Report?

2020-02-19 07:59:32 | Blood disorder startup files for $86M IPO

2020-02-18 07:00:10 | Agios to Present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020

2020-02-14 11:04:04 | Agios' AGIO Q4 Loss Narrower Than Expected, Revenues Beat

2020-02-13 18:42:09 | Edited Transcript of AGIO earnings conference call or presentation 13-Feb-20 1:00pm GMT

2020-02-13 08:55:01 | Agios Pharmaceuticals AGIO Reports Q4 Loss, Tops Revenue Estimates

2020-02-13 07:00:10 | Agios Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-11 07:00:10 | Agios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020

2020-02-06 12:31:05 | Agios Pharmaceuticals AGIO Expected to Beat Earnings Estimates: Should You Buy?

2020-02-05 06:29:25 | If You Had Bought Agios Pharmaceuticals NASDAQ:AGIO Stock Five Years Ago, You'd Be Sitting On A 57% Loss, Today

2020-01-30 07:00:10 | Agios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

2020-01-17 12:19:20 | Analysts: 3 Healthcare Stocks That Could Gain 35% — Or More

2020-01-08 11:26:04 | Incyte's Application for Pemigatinib Gets EMA's Validation

2020-01-07 12:00:05 | What Makes Agios Pharmaceuticals AGIO a New Buy Stock

2019-12-23 07:00:10 | Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

2019-12-17 10:08:03 | Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS

2019-12-17 07:56:25 | The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO

2019-12-16 16:00:10 | Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® ivosidenib for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

2019-12-13 08:40:38 | These Hedge Funds Cashed Out Of Agios Pharmaceuticals Inc AGIO Too Early

2019-12-13 00:45:46 | Edited Transcript of AGIO earnings conference call or presentation 14-Feb-18 1:00pm GMT

2019-12-09 16:19:28 | Here Are The Winners From The Year's Biggest Hematology Meeting

2019-12-09 10:00:10 | Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

2019-12-09 08:00:10 | Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® ivosidenib Treatment in IDH1 Mutant Acute Myeloid Leukemia AML